to Develop Improved Polyvalent Adenovirus Vaccine to Provide a Base for Others Against Viral Agents in Respiratory Illness

摘要

Small lots of live oral Adenovirus type 7 vaccine were produced and tested. Following the reports of efficacy, four large production vaccine lots were completed. Two-hundred-thousand tablets, each containing about 5.5 logs of virus, and 25,000 ml of conventional formalin inactivated vaccine have been made available. Small lots of live oral and formalin inactivated vaccines have been completed for Adenovirus types 1, 2, 5, 14 and 21. New techniques for the production of immunologically potent adenovirus subunit vaccines have been developed and evaluated. These were shown to be free of DNA to the limit of detectability of radio-tracer technology. A small lot has been submitted for clinical evaluation. A variety of myxovirus strains, including influenza, parainfluenza and RS, have been developed for evaluation as live attenuated vaccines. (Author)